•	7	— "
17.4	ALZEN	
ର 💆	AKEK	BO S LLE
© ~~~		

07-20-01

Please type a plus sign (+) inside this box

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. A33626-A 067252.0107

First Inventor Smith et al.

RECOMBINANT

* see attached

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No. EK 839 854 832 US

APPLICATION ELEMENTS	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application			
See MPEP chapter 600 concerning utility patent application contents.	Washington, DC 20231			
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)			
2. Applicant claims small entity status. See 37 CFR 1.27.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)			
3. Specification [Total Pages 74]	a. Computer Readable Form (CRF)			
 Descriptive title of the invention Cross Reference to Related Applications 	b. Specification Sequence Listing on:			
 Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, 	i. CD-ROM or CD-R (2 copies); or			
or a computer program listing appendix	ii. 🗹 paper			
Background of the Invention Brief Summary of the Invention	c. Statements verifying identity of above copies			
- Brief Description of the Drawings (if filed)	ACCOMPANYING APPLICATION PARTS			
- Detailed Description 7 Claim(s) [Total Sheets 7	9. Assignment Papers (cover sheet & document(s))			
Abstract of the Disclosure [Total Sheets 1]	10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney			
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 23]	11. English Translation Document (if applicable)			
5. Oath or Declaration [Total Pages]	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations			
a. Newly executed (original or copy)	13. Preliminary Amendment			
b. Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed)	14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)			
named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	16. Request and Certification under 35 U.S.C. 122			
	(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.			
6 Application Data Sheet. See 37 CFR 1.76	17. Other:			
18. If a CONTINUING APPLICATION, check appropriate box, and supply or in an Application Data Sheet under 37 CFR 1.76:	y the requisite information below and in a preliminary amendment.			
Continuation Divisional Continuation-in-part (CIP)	of prior application No.: 09/611,419			
Prior application information: Examiner TBA	Group Art Unit: 1653			
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the Box 5b, is considered a part of the disclosure of the accompanying continua	tion or divisional application and is hereby incorporated by reference			
The incorporation can only be relied upon when a portion has been inadverted. 19. CORRESPONDE	ntly omitted from the submitted application parts.			
24003	1 ABRA			
Customer Number or Bar Code Label [(Insert Customer No. or Attach bar Custo	or Correspondence address below			
Name				
Address				
City	State Zip Code			
Country	phone Fax			
Name (Print/Type) Rochelle K. Seide	Registration No. (Attorney/Agent) 32,300			
Signature KOMM 1 1 - NAM	Q Data 07-20-2001			

BAKER BOTTS LLP

Addendum Sheet 1

Att Docket #: A33626-A 067252.0107

*Question 4 Addendum 4.a. Drawings are ☐ formal ☑informal
* Question 5 Addendum 5.c. ☐An unsigned oath or declaration is included.
* Question 8 Addendum 8.d. ☐ A sequence submission will follow.
* Question 9 Addendum 9.a. ✓ Assignment documents will follow. 9.b. ☐ Assignment documents have been filed in parent application No.
* Question 11 Addendum 11.a ☐ English translation will follow.
* Question 12 Addendum 12.a ☐ Copies of IDS citations will follow.
* Question 15 Addendum 15.a. ☐ Certified copies of priority documents will follow. 15.b ☐ Certified copies of priority documents have been filed in parent application No.
Use the space below for additional information
Sequence Listing enclosed herewith comprises 53 pages. EK 839 854 877 US
Title (continued): RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN

BAKER BOTTS LE

Serial No:____

Att Docket #: A33626-A 067252.0107 Addendum Sheet 2 18a. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Divisional Continuation-in-part (CIP) Continuation of prior application No.:_____ Prior application information: Group Art Unit: _____ 18b. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation: Divisional Continuation-in-part (CIP) of prior application No.:_____ Prior application information: Examiner ___ Group Art Unit: _____ 18c. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Divisional Continuation-in-part (CIP) Continuation of prior application No.:_____ Prior application information: Amend the specification by inserting before the first line the sentence(s) "This application is a Continuation Divisional Continuation-in-part (CIP) of: "This application is based upon: prior application No.:_____ , incorporated by reference herein, which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: , incorporated by reference herein, prior application No.:__ which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: __ , incorporated by reference herein, prior application No.: which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: _____, incorporated by reference herein, prior application No.:_ which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: prior application No.:___ ___ , incorporated by reference herein, Continuation-in-part (CIP) of: which is a Continuation Divisional which is based upon: _____, incorporated by reference herein prior application No.:____ Priority under 35.U.S.C. §119 is claimed based upon the following applications. Foreign Applications: Country: ___ Filing Date:_ Country: _____ Serial No:_____ Filing Date:___ Serial No:____ Filing Date:_____ Country: ___ Provisional Applications: Serial No:___ Filing Date:_____ Serial No:_____ Filing Date:_____

Filing Date:____



FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 2,174

Compl t if Known				
Application Number				
Filing Date	July 20, 2001			
First Named Inventor	Smith et al.			
Examiner Name				
Group Art Unit				
Attorney Docket No.	A33626-A 067252.0107			

METHOD OF PAYMENT	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES			
Deposit Deposit	Large	Sma		
Account Number 02-4377	Entity Fee	Entit Fee	•	Fee Paid
Denosit	(\$)	(\$)	Fee Description	ree Palu
Account Name Baker Botts LLP	130	65	Surcharge - late filing fee or oath	
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	50	25	Surcharge - late provisional filing fee or cover sheet	
Applicant claims small entity status.	130	130	Non-English specification	
See 37 CFR 1.27	2,520	2,520	For filing a request for ex parte reexamination	
2. Payment Enclosed: Check Credit card Money Other	920*	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	1,840*	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	110	55	Extension for reply within first month	
Large Entity Small Entity	390	195	Extension for reply within second month	
Fee Fee Description (\$) (\$) Fee Paid	890	445	Extension for reply within third month	
710 355 Utility filing fee 710	1,390	695	Extension for reply within fourth month	
320 160 Design filing fee	1,890	945	Extension for reply within fifth month	
490 245 Plant filing fee	310	155	Notice of Appeal	
710 355 Reissue filing fee	310	155	Filing a brief in support of an appeal	
150 75 Provisional filing fee	270	135	Request for oral hearing	
	1,510	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$) 710	110	55	Petition to revive - unavoidable	
2. EXTRA CLAIM FEES	1,240	620	Petition to revive - unintentional	
Fee from Ext <u>ra Claims below Fee Paid</u>	1,240	620	Utility issue fee (or reissue)	
Total Claims 48 -20•• = 28 x 18 = 504	440	220	Design issue fee	
Independent Claims 15 - 3** = 12 x 80 = 960	600	300	Plant issue fee	
Multiple Dependent	130	130	Petitions to the Commissioner	
	50	50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity Fee Fee Fee Description	180	180	Submission of Information Disclosure Stmt	
(\$)	40	40	Recording each patent assignment per	
18 9 Claims in excess of 20	Į.		property (times number of properties)	
80 40 Independent claims in excess of 3	710	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
270 135 Multiple dependent claim, if not paid	710	355	For each additional invention to be	
80 40 ** Reissue independent claims over original patent			examined (37 CFR § 1.129(b))	
18 9 ** Reissue claims in excess of 20	710	355	Request for Continued Examination (RCE)	
and over original patent	900	900	Request for expedited examination	
SUBTOTAL (2) (\$) 1,464	Other fee (specif	y)	of a design application	
**or number previously paid, if greater, For Reissues, see above	*Reduced by Bas	sic Filina	Fee Paid SUBTOTAL (3) (\$) 0	
State of Provided of Paris, in greater, For Newscass, Sale above	/ C		CODIOTAL (3) (47)	

SUBMITTED BY

Name (Print/Type)

Rochelle K. Seide Registration No. (212) 408-2626

Signature

Complete (if applicable)

Telephone (212) 408-2626

Date July 20, 2001